LURAP1L

Across TCGA pan-cancer cohorts, LURAP1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LURAP1L data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LURAP1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LURAP1L expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

LUAD, LIHC, and UCEC are the cancer types where LURAP1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.178	0.813	<.001	21	view →
LIHC	DFS	Median	All	0.083	0.553	.009	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	III,IV	1.000	0.229	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LURAP1L–LUAD (DFS)

Open the LUAD breakdown →